Search
Valsartan
go.drugbank.com/drugs/DB00177ApprovedInvestigationalHowever, this does not prevent the formation of all angiotensin II within the body. … ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.
Synonyms: N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine, (S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valineMixtures: VARTERAL NF® 320 MG / 5 MG, VARTERAL NF® 320 MG / 5 MGSotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigational[L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective. … [L41369] Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.[L39625,L39620]
Oxycodone
go.drugbank.com/drugs/DB00497ApprovedIllicitInvestigational[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Mixtures: Nu-oxycodone/acet, OXYCODON/NALOXON-NX 10/5Padimate O
go.drugbank.com/drugs/DB11570ApprovedIt penetrates human skin, and is shown to induce non-ligatable strand breaks on DNA _in vitro_ and mutagenic effects on yeast i_n vivo_ [A32458]. … Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA [L2153].
Mixtures: Dermatone SPF 23 Lips N Face Protector, Tow Mater Sun Smacker SPF 24 Tow-Tally OrangeOxaliplatin
go.drugbank.com/drugs/DB00526ApprovedInvestigationalOxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. … [A797] Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics.
Synonyms: (SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUMDepemokimab
go.drugbank.com/drugs/DB18846ApprovedInvestigational[A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence.
Dasabuvir
go.drugbank.com/drugs/DB09183ApprovedThe binding sites for non-nucleoside NS5B inhibitors are poorly conserved across HCV genotypes leading to the restriction of Dasabuvir's use to genotype 1 only. … Approved in December 2014 by the FDA, Viekira Pak is indicated for the treatment of HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] [FDA Label].
Categories: Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase InhibitorSynonyms: N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamideAstemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnAstemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Categories: Histamine H1 Antagonists, Non-SedatingTadalafil
go.drugbank.com/drugs/DB00820ApprovedInvestigational[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH.
Products: N/aQuinidine
go.drugbank.com/drugs/DB00908Approved[A38016] It prolongs cellular action potential by blocking sodium and potassium currents. … A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug.